8,097 Shares in Exelixis, Inc. $EXEL Purchased by Verdence Capital Advisors LLC

Verdence Capital Advisors LLC bought a new position in shares of Exelixis, Inc. (NASDAQ:EXEL) in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 8,097 shares of the biotechnology company’s stock, valued at approximately $473,000.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. National Wealth Management Group LLC acquired a new position in shares of Exelixis in the 3rd quarter valued at about $578,000. WealthCare Asset Management LLC acquired a new stake in Exelixis during the third quarter worth approximately $1,590,000. Signaturefd LLC grew its stake in Exelixis by 30.8% during the third quarter. Signaturefd LLC now owns 9,400 shares of the biotechnology company’s stock worth $549,000 after purchasing an additional 2,216 shares during the period. Sowell Financial Services LLC increased its holdings in Exelixis by 78.7% in the third quarter. Sowell Financial Services LLC now owns 9,010 shares of the biotechnology company’s stock worth $526,000 after purchasing an additional 3,967 shares in the last quarter. Finally, Fifth Third Wealth Advisors LLC increased its holdings in Exelixis by 5.1% in the third quarter. Fifth Third Wealth Advisors LLC now owns 9,511 shares of the biotechnology company’s stock worth $556,000 after purchasing an additional 461 shares in the last quarter. Institutional investors and hedge funds own 85.27% of the company’s stock.

Exelixis Stock Performance

EXEL stock opened at $66.20 on Friday. The company has a market capitalization of $16.40 billion, a P/E ratio of 20.82, a price-to-earnings-growth ratio of 1.86 and a beta of 0.47. Exelixis, Inc. has a 52-week low of $36.00 and a 52-week high of $67.52. The business has a 50-day simple moving average of $59.07 and a two-hundred day simple moving average of $50.79.

Exelixis (NASDAQ:EXEL) last posted its earnings results on Thursday, October 29th. The biotechnology company reported $0.94 earnings per share for the quarter, beating analysts’ consensus estimates of $0.89 by $0.05. Exelixis had a return on equity of 42.17% and a net margin of 35.33%. The company had revenue of $658.70 million for the quarter, compared to analyst estimates of $646.51 million. During the same quarter last year, the company earned $0.78 earnings per share. The company’s revenue for the quarter was up 10.2% on a year-over-year basis. As a group, sell-side analysts forecast that Exelixis, Inc. will post 3.19 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on EXEL shares. Wall Street Zen raised Exelixis from a “buy” rating to a “strong-buy” rating in a research note on Saturday, October 24th. Weiss Ratings raised shares of Exelixis from a “buy (a-)” rating to a “buy (a)” rating in a research report on Thursday, October 8th. Barclays raised their price objective on shares of Exelixis from $45.00 to $49.00 and gave the stock an “equal weight” rating in a research report on Tuesday, July 14th. Morgan Stanley lifted their price objective on shares of Exelixis from $50.00 to $53.00 and gave the company an “equal weight” rating in a research note on Thursday, July 23rd. Finally, Leerink Partners downgraded shares of Exelixis from an “outperform” rating to a “market perform” rating and set a $52.00 target price on the stock. in a research report on Thursday, August 6th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $51.50.

Insider Buying and Selling

In related news, Director Mary Beckerle sold 9,812 shares of the stock in a transaction on Monday, August 10th. The stock was sold at an average price of $53.66, for a total value of $526,511.92. Following the completion of the sale, the director directly owned 16,079 shares of the company’s stock, valued at approximately $862,799.14. This represents a 37.90% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 2.60% of the company’s stock.

Exelixis News Roundup

Here are the key news stories impacting Exelixis this week:

• Positive Sentiment: Exelixis reported adjusted earnings of $0.94 per share, exceeding the $0.89 consensus estimate and rising from $0.78 a year earlier. Revenue increased 10.2% year over year to $658.7 million, beating estimates of $646.5 million. Exelixis Surpasses Q3 Earnings and Revenue Estimates
• Positive Sentiment: Profitability and cash generation remained strong: operating profit reached $268.4 million, net income rose 12.7% to $218.1 million, and operating cash flow was $280 million. These results support the investment case for the company’s CABOMETYX-led oncology business. Exelixis Q3 Results
• Positive Sentiment: Exelixis and Bristol-Myers Squibb announced a long-term extension study intended to expand access to their cancer medicines, a development that may support patient retention and the partners’ oncology franchises. Exelixis and BMY Extend Access to Cancer Drugs
• Neutral Sentiment: The earnings-call coverage focused on management’s third-quarter results and corporate update; investors will look for additional detail on CABOMETYX performance, pipeline progress, and future growth during the call. Q3 2026 Earnings Call Transcript
• Negative Sentiment: Reported insider activity showed six sales and no purchases during the past six months. In addition, the cited analyst price-target median of $52 is well below the recent trading level, signaling that some investors may view the stock as fully valued.

Exelixis Company Profile

Exelixis, Inc is a biopharmaceutical company focused on discovering, developing, and commercializing medicines for cancer and other serious diseases. The company’s research programs center primarily on targeted therapies, including treatments designed to inhibit signaling pathways involved in tumor growth and progression.

Exelixis’ lead product is CABOMETYX (cabozantinib), an oral medicine approved in the United States for certain patients with renal cell carcinoma, hepatocellular carcinoma, and differentiated thyroid cancer.